Achieve Life Sciences (ACHV) vs. aTyr Pharma (LIFE) Head-To-Head Analysis

aTyr Pharma (NASDAQ: LIFE) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Profitability

This table compares aTyr Pharma and Achieve Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
aTyr Pharma N/A -87.33% -65.25%
Achieve Life Sciences N/A -126.78% -101.46%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for aTyr Pharma and Achieve Life Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma 0 3 1 0 2.25
Achieve Life Sciences 0 0 0 0 N/A

aTyr Pharma currently has a consensus target price of $5.00, indicating a potential upside of 53.85%. Given aTyr Pharma’s higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Achieve Life Sciences.

Valuation & Earnings

This table compares aTyr Pharma and Achieve Life Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma N/A N/A -$57.85 million ($2.04) -1.59
Achieve Life Sciences $5.06 million 3.42 -$20.12 million ($3.11) -0.47

Achieve Life Sciences has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

58.3% of aTyr Pharma shares are held by institutional investors. Comparatively, 3.3% of Achieve Life Sciences shares are held by institutional investors. 33.3% of aTyr Pharma shares are held by insiders. Comparatively, 35.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

aTyr Pharma beats Achieve Life Sciences on 6 of the 10 factors compared between the two stocks.

aTyr Pharma Company Profile

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Cytisine and OGX-225. These products are designed to block the production of specific proteins that promotes treatment resistance and survival of tumor cells, and are over-produced in response to a variety of cancer treatments. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply